Wedbush set a $38.00 price target on Obseva (NASDAQ:OBSV) in a report released on Monday, TipRanks reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a buy rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th. ValuEngine cut Valero Energy from a hold rating to a sell rating in a research note on Wednesday, May 8th. Finally, Zacks Investment Research upgraded York Water from a sell rating to a hold rating in a research note on Saturday, June 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $28.83.

NASDAQ OBSV opened at $10.63 on Monday. Obseva has a 12 month low of $9.73 and a 12 month high of $19.40. The firm has a 50 day moving average of $11.47. The company has a current ratio of 6.73, a quick ratio of 6.73 and a debt-to-equity ratio of 0.02. The firm has a market cap of $482.06 million, a P/E ratio of -5.57 and a beta of 0.94.

Obseva (NASDAQ:OBSV) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. As a group, equities analysts predict that Obseva will post -2.32 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Barclays PLC increased its position in Obseva by 331.1% during the 4th quarter. Barclays PLC now owns 10,118 shares of the company’s stock worth $128,000 after buying an additional 7,771 shares during the period. Geode Capital Management LLC bought a new position in Obseva during the 4th quarter worth $159,000. Jane Street Group LLC bought a new position in Obseva during the 4th quarter worth $218,000. Weiss Multi Strategy Advisers LLC increased its position in Obseva by 4.5% during the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 21,000 shares of the company’s stock worth $266,000 after buying an additional 905 shares during the period. Finally, United Services Automobile Association increased its position in Obseva by 132.3% during the 4th quarter. United Services Automobile Association now owns 26,480 shares of the company’s stock worth $335,000 after buying an additional 15,080 shares during the period. Hedge funds and other institutional investors own 63.58% of the company’s stock.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Article: Investing in Growth Stocks

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.